Dallas, Texas 08/12/2013 (Financialstrend) – Dendreon Corporation (Nasdaq: DNDN) has made declaration about the outcomes for the second quarterly period ended June 30, 2013.
The company said that its net product proceeds for the second quarterly period remained at $73.3 million as against $80.0 million registered during the same period of last year (2012).
The figure showed a decline of around 8.4 per cent y-o-y and up 8.4 per cent on a sequential basis.
The company’s net loss for the quarterly period under review (second quarter) stood at $68.8 million, or $0.45 a share as against a net loss of $96.1 million recorded during the same period of 2012.
As of June 30, this year, Dendreon Corporation (Nasdaq: DNDN) possessed $280.6 million in cash, cash equivalents, and temporary and long-standing investments as against $429.8 million as of December 31 last year.
“During the second quarterly period ended June 30, 2013, we saw improvement swinging around what was a challenging first quarterly period, with firm growth in hefty accounts where we are concentrated,” stated Mr. John H. Johnson, company’s chairman, president and CEO.
Sturdy growth pointers
Urology remained on the top and had a q-o-q increase of 37 per cent that has been the firm’s most prominent-ever in this particular section. There has been really optimistic reaction getting in from patients, physicians in addition to key-opinion bosses about PROVENGE.
Mr. Johnson stated that the firm will carry on spotlighting improvisation of its utilization through its d-t-c drive.
Dendreon Corporation (NASDAQ:DNDN) declared its deal about principle regarding authorization of securities
Dendreon Corp (NASDAQ:DNDN) declared its contract about principle regarding authorization of securities class action proceedings awaiting in clash with the Western District of Washingtons’s United States District Court, this declaration will settle on the claims announced against all defendants in the formerly disclosed alleged securities class action.